Paricel 20 Tablets: Each enteric coated tablet contains Rabeprazole Sodium INN 20mg.
Paricel ® 20mg is a preparation of Rabeprazole Sodium. It is an antisecretory compound that suppresses gastric acid secretion by inhibiting the gastric H + , K + ATPase at the secretory surface of the gastric parietal cell.
Healing of Erosive or Ulcerative Gastro-Esophageal Reflux Disease (GERD): The recommended adult oral dose is one Paricel ® 20mg tablet for 4 to 8 weeks. For those patients who have not healed after 8 weeks of treatment, an additional 8 weeks course of Paricel ® may be considered.
Maintenance of Healing of Erosive or Ulcerative Gastro-Esophageal Reflux Disease (GERD): The recommended adult oral dose is one Paricel ® 20mg tablet to be taken once daily.
Treatment of Symptomatic Gastro-Esophageal Reflux Disease (GERD): The recommended adult oral dose is one Paricel ® 20mg tablet to be taken once daily for 4 weeks. If symptoms donot resolve completely after 4 weeks, an additional course of treatment may be considered.
Healing of Duodenal Ulcers: The recommended adult oral dose is one Paricel ® 20mg tablet to be taken once daily after the morning meal for a period up to 4 weeks. Mostpatients with duodenal ulcer heal within 4 weeks. A few patients may require additional therapy to achieve healing.
Helicobacter pylori eradication to reduce the risk of Duodenal Ulcer Recurrence (Three drug regimen):
Rabeprazole 20mg Twice daily for 7 days
Amoxycillin 1000mg Twice daily for 7 days
Clarithromycin 500mg Twice daily for 7 days
All three medications should be taken twice daily with the morning and evening meals.
Treatment of pathological hypersecretory conditions including Zollinger-Ellison Syndrome: The recommended adult oral starting dose is 60 mg once daily. Doses should be adjusted to individual patient needs and should continue for as long as clinically indicated. Some patients may require divided doses. Doses up to 100 mg QD and 60 mg BID have been administered.
Reduces gastrointestinal absorption of ketoconazole, itraconazole, and iron salts; increases plasma levels of digoxin (monitor digoxin levels); co-administration with atazanavir is not recommended.
Rabeprazole is contra-indicated in patients with known hypersensitivity to Rabeprazole, substituted benzimidazoles or to any component of the formulation.
Common: Headache, diarrhea, nausea. Less Common: Rhinitis, abdominal pain, asthenia, flatulence, pharyngitis, vomiting, dizziness, influenza-like syndrome, cough, constipation, insomnia.
Overdose
There has been no experience with large overdoses with Rabeprazole. No specific antidote for Rabeprazole is known. Rabeprazole is extensively protein bound and is not readily dialyzable. In the event of over dosage treatment should be symptomatic and supportive. Warnings Clarithromycin should not be used in pregnant women except in clinical circumstances where no alternative therapy is appropriate. If pregnancy occurs while taking Clarithromycin, the patient should be appraised of the potential hazards to the fetus. Amoxycillin: serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients on penicillin therapy. These reactions are more likely to occur in individuals with a history of penicillin hypersensitivity and/or a history of sensitivity to multiple allergens.
Category B. No adequate and well-controlled studies in pregnant women; use during pregnancy only if clearly needed. Lactation: Excretion in breast milk unknown; discontinue nursing or discontinue drug.
Store below 25°C in a cool, dry place. Protect from light and moisture. Keep out of reach of children.